AstraZeneca has announced the launch of its FluMist Home service for delivery of the FluMist intranasal influenza vaccine in the US for the 2025-26 flu season. In September 2024, the nasal vaccine was approved by the FDA for self- or caregiver administration for people up to age 49. According to AstraZeneca, state pharmacy laws will prevent home delivery in a number of states; however, the service will be available to residents of 34 states who can order the nasal spray through a web site.
AstraZeneca US Country President and Senior VP Joris Silon commented, “The launch of FluMist Home is a transformational moment in the evolution of influenza protection, bringing a simple and accessible option directly into the hands of consumers. FluMist Home reflects the growing importance of direct-to-consumer offerings and underscores our commitment to continuous innovation, making it easier for people to get vaccinated and stay protected.”
Read the AstraZeneca press release
